rizatriptan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| serotonin (5-HT1) receptor agonists, sumatriptan derivatives | 2393 | 144034-80-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Rizatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Rizatriptan presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 42 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 14 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.86 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 45 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.90 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 16 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.86 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.20 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 29, 1998 | FDA | MERCK |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Migraine | 393.66 | 14.25 | 294 | 19227 | 103052 | 63366449 |
| Neovascularisation | 130.97 | 14.25 | 36 | 19485 | 1109 | 63468392 |
| Drug ineffective for unapproved indication | 109.94 | 14.25 | 88 | 19433 | 33975 | 63435526 |
| Headache | 102.05 | 14.25 | 424 | 19097 | 632817 | 62836684 |
| Paradoxical drug reaction | 92.26 | 14.25 | 38 | 19483 | 4114 | 63465387 |
| Extrapyramidal disorder | 55.39 | 14.25 | 40 | 19481 | 13244 | 63456257 |
| Anuria | 52.80 | 14.25 | 38 | 19483 | 12513 | 63456988 |
| Swollen tongue | 52.49 | 14.25 | 59 | 19462 | 34741 | 63434760 |
| Contraindicated product administered | 49.05 | 14.25 | 5 | 19516 | 217643 | 63251858 |
| Gallbladder polyp | 47.15 | 14.25 | 15 | 19506 | 772 | 63468729 |
| Nausea | 45.81 | 14.25 | 431 | 19090 | 854040 | 62615461 |
| Death | 44.96 | 14.25 | 30 | 19491 | 374351 | 63095150 |
| Multiple sclerosis relapse | 42.77 | 14.25 | 63 | 19458 | 48415 | 63421086 |
| Dust allergy | 40.46 | 14.25 | 13 | 19508 | 691 | 63468810 |
| Serotonin syndrome | 38.84 | 14.25 | 46 | 19475 | 28636 | 63440865 |
| Hypermobility syndrome | 38.47 | 14.25 | 13 | 19508 | 810 | 63468691 |
| Medication overuse headache | 38.33 | 14.25 | 13 | 19508 | 819 | 63468682 |
| Anxiety | 38.21 | 14.25 | 150 | 19371 | 217391 | 63252110 |
| Pre-existing condition improved | 37.08 | 14.25 | 26 | 19495 | 8218 | 63461283 |
| Swelling face | 35.21 | 14.25 | 67 | 19454 | 63408 | 63406093 |
| Migraine with aura | 34.93 | 14.25 | 17 | 19504 | 2723 | 63466778 |
| Cholecystitis chronic | 33.90 | 14.25 | 27 | 19494 | 10334 | 63459167 |
| Product substitution issue | 32.87 | 14.25 | 32 | 19489 | 15964 | 63453537 |
| Depression | 32.50 | 14.25 | 133 | 19388 | 196359 | 63273142 |
| Dysphonia | 32.48 | 14.25 | 55 | 19466 | 47559 | 63421942 |
| Synovitis | 31.85 | 14.25 | 9 | 19512 | 186909 | 63282592 |
| Purpura senile | 30.74 | 14.25 | 10 | 19511 | 553 | 63468948 |
| Coronary artery dissection | 30.25 | 14.25 | 11 | 19510 | 851 | 63468650 |
| Anaphylactic reaction | 29.79 | 14.25 | 64 | 19457 | 66036 | 63403465 |
| Abdominal discomfort | 29.63 | 14.25 | 33 | 19488 | 320852 | 63148649 |
| Wound | 29.46 | 14.25 | 7 | 19514 | 163256 | 63306245 |
| Carotid artery dissection | 26.79 | 14.25 | 7 | 19514 | 177 | 63469324 |
| Alopecia | 26.72 | 14.25 | 39 | 19482 | 337497 | 63132004 |
| Arthropathy | 26.59 | 14.25 | 20 | 19501 | 234772 | 63234729 |
| Toxicity to various agents | 25.60 | 14.25 | 23 | 19498 | 247227 | 63222274 |
| Product physical issue | 25.46 | 14.25 | 17 | 19504 | 4963 | 63464538 |
| Suicidal ideation | 25.37 | 14.25 | 58 | 19463 | 62363 | 63407138 |
| Hepatic enzyme increased | 24.54 | 14.25 | 16 | 19505 | 202312 | 63267189 |
| Product dose omission issue | 23.85 | 14.25 | 138 | 19383 | 234175 | 63235326 |
| Feeling abnormal | 23.39 | 14.25 | 99 | 19422 | 148293 | 63321208 |
| Acute kidney injury | 23.32 | 14.25 | 28 | 19493 | 263387 | 63206114 |
| Abdominal pain | 23.17 | 14.25 | 162 | 19359 | 293294 | 63176207 |
| Pericarditis | 23.04 | 14.25 | 6 | 19515 | 131573 | 63337928 |
| Chest discomfort | 22.76 | 14.25 | 80 | 19441 | 109889 | 63359612 |
| Cholelithiasis | 22.69 | 14.25 | 45 | 19476 | 43880 | 63425621 |
| Tarsal tunnel syndrome | 22.69 | 14.25 | 8 | 19513 | 566 | 63468935 |
| Paraesthesia | 22.67 | 14.25 | 102 | 19419 | 156864 | 63312637 |
| Dizziness | 22.44 | 14.25 | 216 | 19305 | 429709 | 63039792 |
| Complex regional pain syndrome | 22.41 | 14.25 | 12 | 19509 | 2345 | 63467156 |
| Vestibular disorder | 21.68 | 14.25 | 10 | 19511 | 1421 | 63468080 |
| Sleep apnoea syndrome | 21.68 | 14.25 | 35 | 19486 | 29098 | 63440403 |
| Febrile neutropenia | 21.52 | 14.25 | 5 | 19516 | 118444 | 63351057 |
| Vertigo | 21.48 | 14.25 | 53 | 19468 | 59834 | 63409667 |
| Sinusitis | 21.47 | 14.25 | 131 | 19390 | 226522 | 63242979 |
| Muscle spasms | 21.45 | 14.25 | 100 | 19421 | 156050 | 63313451 |
| Surgery | 21.28 | 14.25 | 39 | 19482 | 35873 | 63433628 |
| Anaemia | 21.22 | 14.25 | 36 | 19485 | 293394 | 63176107 |
| Colitis ischaemic | 21.21 | 14.25 | 21 | 19500 | 10687 | 63458814 |
| Angioedema | 21.10 | 14.25 | 46 | 19475 | 47919 | 63421582 |
| Neutropenia | 21 | 14.25 | 14 | 19507 | 174991 | 63294510 |
| Stress | 20.55 | 14.25 | 56 | 19465 | 67111 | 63402390 |
| Vomiting | 20.44 | 14.25 | 262 | 19259 | 559355 | 62910146 |
| Joint swelling | 20.38 | 14.25 | 44 | 19477 | 327622 | 63141879 |
| Systemic lupus erythematosus | 19.81 | 14.25 | 21 | 19500 | 208897 | 63260604 |
| Allergy to animal | 19.80 | 14.25 | 9 | 19512 | 1237 | 63468264 |
| No adverse event | 19.70 | 14.25 | 41 | 19480 | 41364 | 63428137 |
| Atrioventricular septal defect | 18.84 | 14.25 | 6 | 19515 | 310 | 63469191 |
| Oesophagitis ulcerative | 18.74 | 14.25 | 7 | 19514 | 584 | 63468917 |
| Sensory level abnormal | 18.35 | 14.25 | 5 | 19516 | 149 | 63469352 |
| Somnolence | 18.02 | 14.25 | 105 | 19416 | 178580 | 63290921 |
| Ankylosing spondylitis | 17.95 | 14.25 | 19 | 19502 | 10455 | 63459046 |
| Atrial fibrillation | 17.45 | 14.25 | 7 | 19514 | 116629 | 63352872 |
| Platelet count decreased | 17.32 | 14.25 | 7 | 19514 | 116115 | 63353386 |
| Visual field defect | 17.12 | 14.25 | 15 | 19506 | 6546 | 63462955 |
| Vasospasm | 17.02 | 14.25 | 7 | 19514 | 755 | 63468746 |
| Dyspepsia | 16.73 | 14.25 | 69 | 19452 | 102127 | 63367374 |
| Palate injury | 16.70 | 14.25 | 4 | 19517 | 70 | 63469431 |
| Resorption bone increased | 16.53 | 14.25 | 8 | 19513 | 1266 | 63468235 |
| Weight decreased | 16.40 | 14.25 | 143 | 19378 | 276655 | 63192846 |
| Emotional distress | 16.40 | 14.25 | 33 | 19488 | 32516 | 63436985 |
| Therapeutic response unexpected | 16.00 | 14.25 | 24 | 19497 | 18735 | 63450766 |
| Completed suicide | 15.74 | 14.25 | 13 | 19508 | 145660 | 63323841 |
| Speech disorder | 15.68 | 14.25 | 37 | 19484 | 40592 | 63428909 |
| Broad ligament tear | 15.43 | 14.25 | 3 | 19518 | 18 | 63469483 |
| Wrong technique in product usage process | 15.25 | 14.25 | 48 | 19473 | 62292 | 63407209 |
| Gait inability | 15.06 | 14.25 | 43 | 19478 | 52916 | 63416585 |
| Hemiparaesthesia | 15.06 | 14.25 | 4 | 19517 | 108 | 63469393 |
| Burns third degree | 15.02 | 14.25 | 5 | 19516 | 297 | 63469204 |
| Vision blurred | 15.00 | 14.25 | 62 | 19459 | 91862 | 63377639 |
| Flushing | 15.00 | 14.25 | 54 | 19467 | 75033 | 63394468 |
| Rash | 14.98 | 14.25 | 106 | 19415 | 560765 | 62908736 |
| Sepsis | 14.95 | 14.25 | 15 | 19506 | 153108 | 63316393 |
| Pleural effusion | 14.94 | 14.25 | 5 | 19516 | 93205 | 63376296 |
| Nasal discharge discolouration | 14.71 | 14.25 | 9 | 19512 | 2262 | 63467239 |
| Palpitations | 14.59 | 14.25 | 71 | 19450 | 112699 | 63356802 |
| Facial pain | 14.39 | 14.25 | 17 | 19504 | 10544 | 63458957 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Nightmare | 240.12 | 28.05 | 73 | 2429 | 14318 | 34940111 |
| Sedation | 212.97 | 28.05 | 73 | 2429 | 20933 | 34933496 |
| Nephrolithiasis | 193.91 | 28.05 | 75 | 2427 | 30258 | 34924171 |
| Kounis syndrome | 155.13 | 28.05 | 36 | 2466 | 2482 | 34951947 |
| Hyperhidrosis | 141.93 | 28.05 | 80 | 2422 | 75612 | 34878817 |
| Product used for unknown indication | 127.92 | 28.05 | 26 | 2476 | 957 | 34953472 |
| Nausea | 104.31 | 28.05 | 124 | 2378 | 339784 | 34614645 |
| Drug ineffective | 79.86 | 28.05 | 127 | 2375 | 456624 | 34497805 |
| Migraine | 79.75 | 28.05 | 34 | 2468 | 17444 | 34936985 |
| Arteriospasm coronary | 55.58 | 28.05 | 17 | 2485 | 3365 | 34951064 |
| Product use in unapproved indication | 53.38 | 28.05 | 53 | 2449 | 117446 | 34836983 |
| Renal infarct | 36.32 | 28.05 | 10 | 2492 | 1366 | 34953063 |
| Venous angioma of brain | 32.46 | 28.05 | 5 | 2497 | 34 | 34954395 |
| Therapy partial responder | 28.90 | 28.05 | 14 | 2488 | 9602 | 34944827 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Migraine | 385.10 | 14.97 | 237 | 16797 | 87256 | 79640098 |
| Neovascularisation | 140.99 | 14.97 | 36 | 16998 | 1209 | 79726145 |
| Nightmare | 98.41 | 14.97 | 64 | 16970 | 25797 | 79701557 |
| Drug ineffective for unapproved indication | 98.29 | 14.97 | 84 | 16950 | 51154 | 79676200 |
| Kounis syndrome | 97.17 | 14.97 | 36 | 16998 | 4246 | 79723108 |
| Headache | 96.26 | 14.97 | 332 | 16702 | 653440 | 79073914 |
| Nausea | 93.38 | 14.97 | 427 | 16607 | 956769 | 78770585 |
| Nephrolithiasis | 87.51 | 14.97 | 80 | 16954 | 53211 | 79674143 |
| Product used for unknown indication | 83.55 | 14.97 | 25 | 17009 | 1519 | 79725835 |
| Sedation | 79.60 | 14.97 | 75 | 16959 | 51820 | 79675534 |
| Paradoxical drug reaction | 79.16 | 14.97 | 36 | 16998 | 7149 | 79720205 |
| Drug ineffective | 50.44 | 14.97 | 398 | 16636 | 1080515 | 78646839 |
| Swollen tongue | 49.58 | 14.97 | 53 | 16981 | 42517 | 79684837 |
| Hypermobility syndrome | 48.49 | 14.97 | 13 | 17021 | 529 | 79726825 |
| Death | 48.03 | 14.97 | 31 | 17003 | 566483 | 79160871 |
| Arteriospasm coronary | 47.90 | 14.97 | 25 | 17009 | 6691 | 79720663 |
| Anuria | 45.65 | 14.97 | 37 | 16997 | 20926 | 79706428 |
| Hyperhidrosis | 45.32 | 14.97 | 100 | 16934 | 151392 | 79575962 |
| Dust allergy | 42.67 | 14.97 | 15 | 17019 | 1521 | 79725833 |
| Swelling face | 41.81 | 14.97 | 63 | 16971 | 71149 | 79656205 |
| Dysphonia | 41.78 | 14.97 | 56 | 16978 | 56816 | 79670538 |
| Extrapyramidal disorder | 41.08 | 14.97 | 36 | 16998 | 22643 | 79704711 |
| Gallbladder polyp | 40.76 | 14.97 | 13 | 17021 | 977 | 79726377 |
| Medication overuse headache | 37.65 | 14.97 | 12 | 17022 | 900 | 79726454 |
| Acute kidney injury | 35.74 | 14.97 | 35 | 16999 | 519369 | 79207985 |
| Migraine with aura | 34.43 | 14.97 | 15 | 17019 | 2690 | 79724664 |
| Cholecystitis chronic | 34.01 | 14.97 | 23 | 17011 | 9883 | 79717471 |
| Anaemia | 31.76 | 14.97 | 29 | 17005 | 444986 | 79282368 |
| Coronary artery dissection | 31.13 | 14.97 | 11 | 17023 | 1133 | 79726221 |
| Febrile neutropenia | 30.76 | 14.97 | 6 | 17028 | 230993 | 79496361 |
| Purpura senile | 30.50 | 14.97 | 9 | 17025 | 521 | 79726833 |
| Anxiety | 30.28 | 14.97 | 119 | 16915 | 248393 | 79478961 |
| Multiple sclerosis relapse | 29.95 | 14.97 | 43 | 16991 | 46490 | 79680864 |
| Colitis ischaemic | 29.06 | 14.97 | 25 | 17009 | 15334 | 79712020 |
| Depression | 29.03 | 14.97 | 107 | 16927 | 216683 | 79510671 |
| Dyspepsia | 27.28 | 14.97 | 67 | 16967 | 108620 | 79618734 |
| Neutropenia | 26.81 | 14.97 | 14 | 17020 | 287696 | 79439658 |
| Atrioventricular septal defect | 26.71 | 14.97 | 6 | 17028 | 115 | 79727239 |
| Product use in unapproved indication | 26.64 | 14.97 | 115 | 16919 | 250244 | 79477110 |
| Tarsal tunnel syndrome | 26.09 | 14.97 | 8 | 17026 | 528 | 79726826 |
| Paraesthesia | 25.28 | 14.97 | 89 | 16945 | 176234 | 79551120 |
| Product substitution issue | 24.97 | 14.97 | 26 | 17008 | 20230 | 79707124 |
| Carotid artery dissection | 24.71 | 14.97 | 7 | 17027 | 350 | 79727004 |
| Chest discomfort | 24.56 | 14.97 | 75 | 16959 | 137969 | 79589385 |
| Abdominal pain | 24.15 | 14.97 | 154 | 16880 | 389415 | 79337939 |
| Sinusitis | 24.11 | 14.97 | 94 | 16940 | 195407 | 79531947 |
| Vasospasm | 23.78 | 14.97 | 9 | 17025 | 1125 | 79726229 |
| Reversible cerebral vasoconstriction syndrome | 23.59 | 14.97 | 12 | 17022 | 3045 | 79724309 |
| Thrombocytopenia | 23.14 | 14.97 | 14 | 17020 | 265245 | 79462109 |
| Burns third degree | 22.95 | 14.97 | 7 | 17027 | 454 | 79726900 |
| Insomnia | 22.63 | 14.97 | 108 | 16926 | 245062 | 79482292 |
| Serotonin syndrome | 22.49 | 14.97 | 37 | 16997 | 44990 | 79682364 |
| Complex regional pain syndrome | 21.73 | 14.97 | 10 | 17024 | 2038 | 79725316 |
| Anaphylactic reaction | 21.41 | 14.97 | 52 | 16982 | 83691 | 79643663 |
| Atrial fibrillation | 20.99 | 14.97 | 8 | 17026 | 197878 | 79529476 |
| Pancytopenia | 20.65 | 14.97 | 5 | 17029 | 165740 | 79561614 |
| Platelet count decreased | 20.43 | 14.97 | 8 | 17026 | 194656 | 79532698 |
| Vomiting | 20.17 | 14.97 | 224 | 16810 | 665604 | 79061750 |
| Hypotension | 19.94 | 14.97 | 40 | 16994 | 440277 | 79287077 |
| Nasal discharge discolouration | 19.76 | 14.97 | 10 | 17024 | 2511 | 79724843 |
| Venous angioma of brain | 19.71 | 14.97 | 4 | 17030 | 46 | 79727308 |
| Sensory level abnormal | 19.58 | 14.97 | 5 | 17029 | 168 | 79727186 |
| Cholelithiasis | 19.53 | 14.97 | 38 | 16996 | 52626 | 79674728 |
| Ankylosing spondylitis | 19.39 | 14.97 | 18 | 17016 | 12187 | 79715167 |
| Toxicity to various agents | 19.34 | 14.97 | 38 | 16996 | 421502 | 79305852 |
| Malignant neoplasm progression | 19.26 | 14.97 | 3 | 17031 | 135987 | 79591367 |
| Angioedema | 19.21 | 14.97 | 47 | 16987 | 75988 | 79651366 |
| Dizziness | 19.21 | 14.97 | 184 | 16850 | 526257 | 79201097 |
| Renal impairment | 19.19 | 14.97 | 5 | 17029 | 157778 | 79569576 |
| Emotional distress | 18.83 | 14.97 | 32 | 17002 | 39937 | 79687417 |
| Injection site swelling | 18.70 | 14.97 | 35 | 16999 | 47097 | 79680257 |
| Sepsis | 18.68 | 14.97 | 18 | 17016 | 269410 | 79457944 |
| Flushing | 18.63 | 14.97 | 51 | 16983 | 88217 | 79639137 |
| Allergy to animal | 18.38 | 14.97 | 8 | 17026 | 1431 | 79725923 |
| Resorption bone increased | 18.19 | 14.97 | 8 | 17026 | 1467 | 79725887 |
| Palate injury | 17.84 | 14.97 | 4 | 17030 | 76 | 79727278 |
| Speech disorder | 17.47 | 14.97 | 37 | 16997 | 54408 | 79672946 |
| Pain | 17.47 | 14.97 | 228 | 16806 | 703574 | 79023780 |
| Therapy partial responder | 17.39 | 14.97 | 20 | 17014 | 17377 | 79709977 |
| Gastrointestinal haemorrhage | 17.36 | 14.97 | 5 | 17029 | 147714 | 79579640 |
| Contraindicated product administered | 17.33 | 14.97 | 6 | 17028 | 157532 | 79569822 |
| Vestibular disorder | 17.11 | 14.97 | 9 | 17025 | 2446 | 79724908 |
| Hypersensitivity | 17.06 | 14.97 | 105 | 16929 | 262134 | 79465220 |
| Throat tightness | 16.81 | 14.97 | 25 | 17009 | 27882 | 79699472 |
| Oesophagitis ulcerative | 16.39 | 14.97 | 7 | 17027 | 1196 | 79726158 |
| Renal infarct | 16.34 | 14.97 | 9 | 17025 | 2682 | 79724672 |
| Atheroembolism | 16.18 | 14.97 | 5 | 17029 | 339 | 79727015 |
| Device difficult to use | 16.17 | 14.97 | 17 | 17017 | 13368 | 79713986 |
| Wrong technique in product usage process | 15.91 | 14.97 | 43 | 16991 | 73832 | 79653522 |
| Asthma | 15.87 | 14.97 | 64 | 16970 | 135031 | 79592323 |
| Disease progression | 15.70 | 14.97 | 10 | 17024 | 184352 | 79543002 |
| Hepatic enzyme increased | 15.42 | 14.97 | 10 | 17024 | 182600 | 79544754 |
| Blood creatinine increased | 15.26 | 14.97 | 7 | 17027 | 155050 | 79572304 |
| Cardiac failure | 15.23 | 14.97 | 7 | 17027 | 154835 | 79572519 |
| Perfume sensitivity | 14.98 | 14.97 | 6 | 17028 | 873 | 79726481 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N02CC04 | NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Selective serotonin (5HT1) agonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018490 | Serotonin Agents |
| MeSH PA | D017366 | Serotonin Receptor Agonists |
| FDA MoA | N0000175763 | Serotonin 1b Receptor Agonists |
| FDA MoA | N0000175764 | Serotonin 1d Receptor Agonists |
| FDA EPC | N0000175765 | Serotonin-1b and Serotonin-1d Receptor Agonist |
| CHEBI has role | CHEBI:35472 | anti-inflammatory drugs |
| CHEBI has role | CHEBI:35941 | serotonin agonists |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Migraine | indication | 37796009 | DOID:6364 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Hemiplegic migraine | contraindication | 59292006 | |
| Prinzmetal angina | contraindication | 87343002 | |
| Chronic renal failure syndrome | contraindication | 90688005 | |
| Angina pectoris | contraindication | 194828000 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Cardiovascular event risk | contraindication | 395112001 | |
| Peripheral vascular disease | contraindication | 400047006 | |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Hypertensive urgency | contraindication | 443482000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.75 | acidic |
| pKa2 | 8.28 | Basic |
| pKa3 | 3.56 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 6.90 | WOMBAT-PK | CHEMBL | |||
| 5-hydroxytryptamine receptor 1D | GPCR | AGONIST | Ki | 7.90 | WOMBAT-PK | CHEMBL | |||
| 5-hydroxytryptamine receptor 2C | GPCR | IC50 | 5.10 | CHEMBL | |||||
| Cytochrome P450 2D6 | Enzyme | Ki | 4.85 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 1F | GPCR | AGONIST | Ki | 6.80 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 1E | GPCR | AGONIST | Ki | 6.80 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.85 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | IC50 | 5.10 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | IC50 | 5.20 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | IC50 | 7.30 | CHEMBL | |||||
| Serotonin 3 (5-HT3) receptor | Ion channel | IC50 | 5.40 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021122 | VUID |
| N0000148576 | NUI |
| D00675 | KEGG_DRUG |
| 145202-66-0 | SECONDARY_CAS_RN |
| 4021122 | VANDF |
| 4021123 | VANDF |
| C0297635 | UMLSCUI |
| CHEBI:48273 | CHEBI |
| CHEMBL905 | ChEMBL_ID |
| CHEMBL1201032 | ChEMBL_ID |
| DB00953 | DRUGBANK_ID |
| C093622 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5078 | PUBCHEM_CID |
| 51 | IUPHAR_LIGAND_ID |
| 7474 | INN_ID |
| 51086HBW8G | UNII |
| 237082 | RXNORM |
| 196735 | MMSL |
| 7484 | MMSL |
| d04328 | MMSL |
| 007571 | NDDF |
| 007572 | NDDF |
| 108411001 | SNOMEDCT_US |
| 108412008 | SNOMEDCT_US |
| 363573000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| MAXALT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-0266 | TABLET | 5 mg | ORAL | NDA | 27 sections |
| MAXALT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-0267 | TABLET | 10 mg | ORAL | NDA | 27 sections |
| MAXALT-MLT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3800 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | NDA | 27 sections |
| MAXALT-MLT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3801 | TABLET, ORALLY DISINTEGRATING | 10 mg | ORAL | NDA | 27 sections |
| Rizatriptan Benzoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7471 | TABLET | 5 mg | ORAL | ANDA | 25 sections |
| Rizatriptan Benzoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7472 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
| Rizatriptan Benzoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1403 | TABLET | 5 mg | ORAL | ANDA | 28 sections |
| Rizatriptan Benzoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1404 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
| MAXALT-MLT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-144 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | NDA | 29 sections |
| MAXALT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-461 | TABLET | 10 mg | ORAL | NDA | 29 sections |
| MAXALT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-956 | TABLET | 10 mg | ORAL | NDA | 29 sections |
| Rizatriptan Benzoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-268 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | ANDA | 23 sections |
| Rizatriptan Benzoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-269 | TABLET, ORALLY DISINTEGRATING | 10 mg | ORAL | ANDA | 23 sections |
| Rizatriptan Benzoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-316 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Rizatriptan Benzoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-316 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
| Rizatriptan Benzoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-317 | TABLET | 10 mg | ORAL | ANDA | 23 sections |
| Rizatriptan Benzoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-317 | TABLET | 10 mg | ORAL | ANDA | 23 sections |
| Rizatriptan Benzoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-462 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
| Rizatriptan Benzoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-463 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
| Rizatriptan | Human Prescription Drug Label | 1 | 33342-087 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 25 sections |
| Rizatriptan | Human Prescription Drug Label | 1 | 33342-087 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 25 sections |
| Rizatriptan | Human Prescription Drug Label | 1 | 33342-088 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 25 sections |
| Rizatriptan | Human Prescription Drug Label | 1 | 33342-088 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 25 sections |
| rizatriptan benzoate | Human Prescription Drug Label | 1 | 33342-093 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | ANDA | 26 sections |
| rizatriptan benzoate | Human Prescription Drug Label | 1 | 33342-093 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | ANDA | 26 sections |
| rizatriptan benzoate | Human Prescription Drug Label | 1 | 33342-093 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | ANDA | 26 sections |
| rizatriptan benzoate | Human Prescription Drug Label | 1 | 33342-094 | TABLET, ORALLY DISINTEGRATING | 10 mg | ORAL | ANDA | 26 sections |
| rizatriptan benzoate | Human Prescription Drug Label | 1 | 33342-094 | TABLET, ORALLY DISINTEGRATING | 10 mg | ORAL | ANDA | 26 sections |
| rizatriptan benzoate | Human Prescription Drug Label | 1 | 33342-094 | TABLET, ORALLY DISINTEGRATING | 10 mg | ORAL | ANDA | 26 sections |
| RIZATRIPTAN BENZOATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43817-133 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | ANDA | 21 sections |